NCT01627054View on ClinicalTrials.gov

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 27, 2012

Primary Completion Date

March 21, 2014

Study Completion Date

February 13, 2015

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

AT7519M

Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)

Trial Locations (3)

R3E 0V9

CancerCare Manitoba, Winnipeg

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK